长春瑞宾联合奥沙利铂治疗晚期食管癌

Vinorelbin Gnnbined with Qxaciplain in the Patients with Advanced Esophageal Cancer

目的:观察长春瑞宾联合奥沙利铂治疗晚期食管癌的疗效及不良反应。方法:经影像及病理组织学诊断的晚期食管癌28例,静脉滴注奥沙利铂L-OHP135mg/m22h,(d1);静脉注射长春瑞宾25mg/m210min,(d1、d8),21d重复为1周期,所有患者至少接受2个周期的治疗。结果:28例均可评价疗效,总有效率60.71%。初治病例12例,有效率66.67%;复治病例16例。有效率56.25%。在疼痛缓解,全身情况明显改善,生存质量和KPS评分提高等方面均取得了较好的疗效。主要不良反应为骨髓抑制,外周神经毒性,恶心、呕吐等。无治疗相关死亡者。结论:奥沙利铂联合长春瑞宾治疗晚期食管癌缓解率较高,毒性相对较低,值得进一步临床研究。

Objective： To observe the efficacy and toxicity of vinorelbin combined with oxaciplain in the patients with advanced esophageal cancer. Methods： Twenty eight advanced esophageal cancer confirmed by maging and pathday findings were enrolled in this study. The chemotherapy was comprised of L-OHP 135mg/m^2 infusion for two hours, followed by ten minutes intravenous bolus of vinorelbin 25 mg/ m^2 , d1 ,d8,repeated every 21 days. All patients were received at least two cycles of the treatment. Results： The total efficacy rate was 60. 71%. The efficacy rate of twelve the first treatment patients was 66. 67%. The efficacy rate of sixteen recurrrnt patients was 56. 25%. The clinical benifits included pain relief,general influence improvement,quality of life and KPS increase,etc. The major toxicity included peripheral nerve toxicity,nausea,vomiting and so on. No treatment-related death occurred. Conclusion：Oxaliplatin combined with vinorelbin for treatment of advanced esophageal cancer is effective and has mild toxicity. Further clinical investigation should be warranted.